Register entry
- Registered sites
- 0
- Active NDC listings
- 3
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
33 active NDC listings: 3 human prescription drug. By marketing category: BLA 3.
| Dosage form | NDCs |
|---|---|
| kit | 2 |
| injection, solution | 1 |
| Route | NDCs |
|---|---|
| subcutaneous | 2 |
| intravenous | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| theratechnologies inc. | 3 |
Catalogue
Marketed products
3| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| EGRIFTA SV | tesamorelin | kit, subcutaneous | 62064-241BLA |
| EGRIFTA WR | tesamorelin | kit, subcutaneous | 62064-381BLA |
| TROGARZO | ibalizumab | injection, solution, intravenous | 62064-122BLA |
Enquiry
Common questions
- Is Theratechnologies Inc. FDA approved?
- Theratechnologies Inc. holds no registered establishment of its own; 3 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Theratechnologies Inc. make?
- 3 products are listed under Theratechnologies Inc. in the openFDA NDC Directory, most often as kit; injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.